公开(公告)号：US20240035048A1

公开(公告)日：2024-02-01

申请号：US18217352

申请日：2023-06-30

Applicant: The Broad Institute, Inc. ,  Massachusetts Institute of Technology

Inventor： Feng ZHANG

IPC: C12N15/90 ,  A01K67/027 ,  C12N9/22 ,  C12N15/10 ,  C12N15/63 ,  C12N15/86 ,  C12N15/01 ,  C12N15/85 ,  C12N15/82 ,  C12N9/96

CPC classification number: C12N15/907 ,  A01K67/0275 ,  C12N9/22 ,  C12N15/102 ,  C12N15/63 ,  C12N15/90 ,  C12N15/86 ,  C12N15/01 ,  C12N15/85 ,  A01K67/0278 ,  C12N15/8213 ,  C12N15/8509 ,  C12N9/96 ,  A01K2227/105 ,  A01K2217/052 ,  A01K2217/072 ,  A01K2267/03 ,  A01K2217/05 ,  A01K2217/07 ,  C12N2800/22

Abstract: The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.

公开(公告)号：US11877565B2

公开(公告)日：2024-01-23

申请号：US14806802

申请日：2015-07-23

Applicant: Erasmus University Medical Center ,  Roger Kingdon Craig

Inventor： Roger Kingdon Craig ,  Franklin Gerardus Grosveld ,  Richard Wilhelm Janssens ,  Marinus Johannes Van Haperen

IPC: A01K67/027 ,  C12P21/00 ,  C07K16/00 ,  C12N15/85

CPC classification number: A01K67/0278 ,  A01K67/0276 ,  C12P21/005 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/01 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/56 ,  C12N15/8509

Abstract: A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.

公开(公告)号：US11825820B2

公开(公告)日：2023-11-28

申请号：US15940387

申请日：2018-03-29

Applicant: Mark Trifiro ,  Miltiadis Paliouras ,  Lenore K. Beitel ,  Carlos Alvarado

Inventor： Mark Trifiro ,  Miltiadis Paliouras ,  Lenore K. Beitel ,  Carlos Alvarado

IPC: A01K67/027 ,  C07K14/72

CPC classification number: A01K67/0278 ,  C07K14/721 ,  A01K2217/072 ,  A01K2217/203 ,  A01K2227/105 ,  A01K2267/035 ,  A01K2267/0393

Abstract: A knock-in non-human mammal comprising a recombinant androgen receptor (AR) cassette containing an exogenous human polyglutamine (polyQ) tract encoding sequence in exon 1, wherein the human polyQ tract encoding sequence is stably integrated into the genome of the animal. Also provided are recombinant cells, fertilized eggs and tissues. The resulting animal displays a wide range of phenotypes, best characterized as Metabolic Syndrome and can be used in screening and other assays.

公开(公告)号：US11820810B2

公开(公告)日：2023-11-21

申请号：US16886394

申请日：2020-05-28

Applicant: Kymab Limited

Inventor： Allan Bradley ,  Glenn Friedrich ,  E-Chiang Lee ,  Mark Strivens ,  Nicholas England

IPC: C40B50/06 ,  C07K16/00 ,  C40B40/10 ,  C07K16/46 ,  A01K67/027 ,  C12N15/85 ,  C07H21/04 ,  C12N15/63

CPC classification number: C07K16/00 ,  C40B40/10 ,  C40B50/06 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2227/105 ,  C07H21/04 ,  C07K16/46 ,  C07K16/462 ,  C12N15/63 ,  C12N15/8509

Abstract: The invention relates to the provision of antibody therapeutics and prophylactics that are tailored specifically for human use. The present invention provides libraries, vertebrates and cells, such as transgenic mice or rats or transgenic mouse or rat cells. Furthermore, the invention relates to methods of using the vertebrates to isolate antibodies or nucleotide sequences encoding antibodies. Antibodies, heavy chains, polypeptides, nucleotide sequences, pharmaceutical compositions and uses are also provided by the invention.

公开(公告)号：US20230363362A1

公开(公告)日：2023-11-16

申请号：US18025990

申请日：2021-09-17

Applicant: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Inventor： Yuelei Shen ,  Jiawei Yao ,  Yanan Guo ,  Yang Bai ,  Chengzhang Shang

IPC: A01K67/027 ,  C07K14/72 ,  C12N15/85

CPC classification number: A01K67/0278 ,  C07K14/723 ,  C12N15/8509 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/0362

Abstract: This disclosure relates to genetically modified animal expressing human or chimeric (e.g., humanized) GLP1R, and methods of use thereof.

公开(公告)号：US20230232797A1

公开(公告)日：2023-07-27

申请号：US18175010

申请日：2023-02-27

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Qing Fang ,  Chia-Jen Siao ,  Dan Chalothorn ,  KehDih Lai ,  Leah Sabin ,  Rachel Sattler ,  Brian Zambrowicz ,  Lori Morton

IPC: A01K67/027 ,  A61K49/00 ,  C07K14/76 ,  C12N15/85

CPC classification number: A01K67/0278 ,  A61K49/0008 ,  C07K14/76 ,  C12N15/8509 ,  A01K2207/15 ,  A01K2227/105 ,  A01K2267/03 ,  C12N2015/8527

Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized albumin (ALB) locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized albumin locus express a human albumin protein or a chimeric albumin protein, fragments of which are from human albumin. Methods are provided for using such non-human animals comprising a humanized albumin locus to assess in vivo efficacy of human-albumin-targeting reagents such as nuclease agents designed to target human albumin.

公开(公告)号：US20230232796A1

公开(公告)日：2023-07-27

申请号：US18002228

申请日：2021-06-25

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Susannah Brydges ,  Christos Kyratsous ,  Alina Baum

IPC: A01K67/027 ,  C12N9/48 ,  C12N15/90 ,  A61K49/00

CPC classification number: A01K67/0278 ,  C12N9/485 ,  C12Y304/17023 ,  C12N15/907 ,  A61K49/0008 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2267/0337 ,  A01K2227/105

Abstract: Non-human animal cells and non-human animals comprising a humanized ACE2 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized ACE2 locus express a human ACE2 protein or a chimeric ACE2 protein, fragments of which are from human ACE2. Methods are also provided for using such non-human animals comprising a humanized ACE2 locus to assess in vivo ACE2 activity, e.g., coronavirus infection and/or the treatment or prevention thereof.

公开(公告)号：US20230189773A1

公开(公告)日：2023-06-22

申请号：US18069358

申请日：2022-12-21

Applicant: David Gutmann ,  Corina Anastasaki

Inventor： David Gutmann ,  Corina Anastasaki

IPC: A01K67/027 ,  C12N5/079 ,  G01N33/50

CPC classification number: A01K67/0278 ,  C12N5/0622 ,  G01N33/5088 ,  G01N33/5011 ,  C12N2506/45 ,  C12N2500/38 ,  C12N2501/235 ,  C12N2501/33 ,  C12N2501/105 ,  C12N2501/115 ,  A01K2207/15 ,  A01K2207/12 ,  A01K2217/056 ,  A01K2227/105 ,  A01K2267/0331

Abstract: Among the various aspects of the present disclosure is the provision of engineered cells, animal models, and uses thereof for modeling low grade glioma (LGG). An aspect of the present disclosure provides for a population of cells engineered to silence, downregulate, knock out, or reduce or knock down Cxcl10 expression. Another aspect of the present disclosure provides for an animal engineered to be deficient in Cxcl10, downregulate or reduce expression of Cxcl10, knock out Cxcl10, or knock down Cxcl10 (e.g., Cxcl10−/− mice). Yet another aspect of the present disclosure provides for a method of growing tumor cell lines or patient-derived xenografts for LGG tumors in an animal (e.g., mouse, rat) including providing a mouse or rat harboring somatic homozygous deletion in the Rag1 or Cxcl10 gene, and implanting an amount of the cells in mice sufficient to grow a tumor.

公开(公告)号：US20230183752A1

公开(公告)日：2023-06-15

申请号：US18049724

申请日：2022-10-26

Applicant: UNIVERSITY OF MASSACHUSETTS

Inventor： Michael P. CZECH ,  Yuefei SHEN

IPC: C12N15/90 ,  A61K47/64 ,  A61K47/54 ,  A61P3/04 ,  A01K67/027 ,  A61K9/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  C07K14/47 ,  C12N5/077 ,  C12N9/22 ,  C12N9/96 ,  C12N15/113

CPC classification number: C12N15/907 ,  A61K47/64 ,  A61K47/549 ,  A61P3/04 ,  A01K67/0278 ,  A61K9/0019 ,  C07K7/06 ,  C07K7/08 ,  C07K14/003 ,  C07K14/4702 ,  C12N5/0653 ,  C12N9/22 ,  C12N9/96 ,  C12N15/113 ,  A01K2207/12 ,  A01K2217/07 ,  A01K2227/105 ,  A01K2267/0362

Abstract: Complexes comprising a nucleic acid-guided endonuclease, a sequence-specific targeting nucleic acid and an amphipathic helical peptide are provided. Compositions and methods for delivery of complexes comprising a nucleic acid-guided endonuclease, a sequence-specific targeting nucleic acid and an amphipathic helical peptide to mammals for both research and therapeutic use are provided. Methods of treating or reducing one or more symptoms of type 2 diabetes, prediabetes and/or gestational diabetes are provided.

公开(公告)号：US20230172171A1

公开(公告)日：2023-06-08

申请号：US17922692

申请日：2021-05-21

Applicant: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Inventor： Yuelei Shen ,  Yang Bai ,  Chaoshe Guo ,  Meiling Zhang ,  Rui Huang ,  Chengzhang Shang

IPC: A01K67/027 ,  A61K49/00 ,  C07K14/705 ,  C12N15/90

CPC classification number: A01K67/0278 ,  A61K49/0008 ,  C07K14/7056 ,  C07K14/70596 ,  C12N15/907 ,  A01K2217/15 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/03 ,  C12N2015/8527

Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD94 and/or NKG2A, and methods of use thereof.